HC Wainwright reaffirmed their neutral rating on shares of Assembly Biosciences (NASDAQ:ASMB - Free Report) in a research report sent to investors on Monday, Benzinga reports.
Separately, StockNews.com cut Assembly Biosciences from a hold rating to a sell rating in a research note on Thursday.
Check Out Our Latest Analysis on Assembly Biosciences
Assembly Biosciences Trading Down 3.0 %
Shares of ASMB traded down $0.40 during trading hours on Monday, reaching $12.90. The stock had a trading volume of 18,949 shares, compared to its average volume of 29,521. The firm has a 50-day simple moving average of $12.22 and a 200 day simple moving average of $10.60. Assembly Biosciences has a 12 month low of $7.69 and a 12 month high of $20.04. The company has a market capitalization of $70.69 million, a price-to-earnings ratio of -0.76 and a beta of 0.57.
Insider Buying and Selling at Assembly Biosciences
In related news, major shareholder Alexander Schornstein acquired 24,999 shares of the company's stock in a transaction on Wednesday, January 17th. The shares were acquired at an average cost of $9.36 per share, for a total transaction of $233,990.64. Following the purchase, the insider now owns 655,357 shares in the company, valued at $6,134,141.52. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 4.10% of the company's stock.
Hedge Funds Weigh In On Assembly Biosciences
A number of hedge funds and other institutional investors have recently made changes to their positions in ASMB. JPMorgan Chase & Co. boosted its holdings in shares of Assembly Biosciences by 15,633.0% in the 1st quarter. JPMorgan Chase & Co. now owns 14,789 shares of the biopharmaceutical company's stock worth $30,000 after buying an additional 14,695 shares during the last quarter. Charles Schwab Investment Management Inc. purchased a new position in shares of Assembly Biosciences in the 1st quarter worth about $106,000. State Street Corp boosted its holdings in shares of Assembly Biosciences by 15.7% in the 1st quarter. State Street Corp now owns 145,335 shares of the biopharmaceutical company's stock worth $299,000 after buying an additional 19,712 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of Assembly Biosciences by 123.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 123,772 shares of the biopharmaceutical company's stock worth $255,000 after buying an additional 68,411 shares during the last quarter. Finally, Jane Street Group LLC purchased a new position in shares of Assembly Biosciences in the 1st quarter worth about $27,000. 19.92% of the stock is owned by hedge funds and other institutional investors.
About Assembly Biosciences
(
Get Free Report)
Assembly Biosciences, Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's next-generation HBV core inhibitors include ABI-4334, which is in Phase 1a studies for the treatment of HBV; and ABI-H3733, which is in Phase 1b clinical study.
Recommended Stories
Before you consider Assembly Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Assembly Biosciences wasn't on the list.
While Assembly Biosciences currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
